Sign up for ICER's Weekly View Newsletter

 

Weekly View


August 21, 2026

From the desk of Priya Ranade

Good morning, everyone.

ICER announced a new assessment for Huntington’s disease yesterday. We’ll examine ifezuntrigene inilparvovec (uniQure N.V.), also known as AMT-130.

 

Consistent with ICER’s process for announcing new assessments, we have spent the past five weeks conducting outreach and engaging with targeted stakeholders, including relevant patient groups and clinical experts. Based on this preliminary cross-stakeholder engagement, ICER has posted a Draft Scoping Document outlining how we plan to conduct this assessment, which will be open to public comment until September 11th.

Let's see what else happened this week...

 

ICER in the News

 

New hypertension drugs show no advantage over older generics

Managed Healthcare Executive

ICER recently released a Draft Evidence Report assessing the comparative clinical effectiveness and value of two treatments for uncontrolled hypertension:

 

  • baxdrostat (Baxfendy™, AstraZeneca)

 

  • lorundrostat (Mineralys Therapeutics, Inc.)

 

This preliminary draft marks the midpoint of ICER’s eight-month process of assessing this treatment, and the findings within this document should not be interpreted as ICER’s final conclusions. ICER is accepting public comments on the Draft Report until September 9th.


Endpoints News, FiercePharma, PharmaPhorum, and AJMC also covered the report.

 
Pharmaceutical News

MUST READS


How health care costs are undermining America’s public-sector employers

STAT

STAT’s Bob Herman published part four of the series, “Out of Pocket, Out of Reach.” This week’s article examines how local and state governments are dealing with ballooning health care costs:

 

“Raising taxes to offset surging health care costs creates an uproar, but cutting benefits or raising workers’ premiums also isn’t palatable for a heavily unionized workforce that expects richer benefits in return for lower salaries.

 

State and local governments, perhaps more than ever, are bending under the weight of their health care expenses. Premiums are skyrocketing by double digits across public worker plans in Arkansas, California, Colorado, Missouri, Nevada, and even the federal government. In New Jersey — a state beleaguered by waste and high costs in its public health plans — teachers and other school workers face premium hikes of 34% next year.“

Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting

Endpoints News

List prices for brand-name drugs have declined significantly in 2026. But the reasons behind it may have more to do with a Biden-era law than any of the Trump administration’s recent initiatives, experts told Endpoints News. Wednesday’s Consumer Price Index showed a nearly 1% drop in drug prices for July, with the administration pointing to a nearly 5% drop in prescription drug prices for the first 19 months of President Donald Trump’s second term. But the CPI does not include physician-administered biologics and other specialty drugs that are growing in numbers and can be the most expensive drugs in the entire health system.

Insurers denied between 12% to 18% of prior authorization requests in 2025: KFF

Fierce Healthcare

Insurers denied between 12% and 18% of standard prior authorization requests across market segments in 2025, a new analysis from KFF found. Researchers analyzed Medicare Advantage, Medicaid managed care and Affordable Care Act (ACA) federally facilitated Marketplace (FFM) websites from insurers that had at least 2.5% market share of enrollment in respective segments. Data was collected from 14 unique insurers, representing approximately 71 million enrollees.


On average, 12% of standard prior authorization requests and 10% of expedited requests were denied in Medicare Advantage; 14% of standard requests and 12% of expedited requests were denied in Medicaid managed care; and 18% of standard requests and 16% of expedited requests were denied in ACA FFMs.

Trump Taps Dr. Heidi Overton to Lead FDA

The Wall Street Journal

President Trump has selected one of his top White House health aides, Dr. Heidi Overton, as his next choice to lead the Food and Drug Administration, people familiar with the matter said.


Overton, who helps lead the Domestic Policy Council, has guided many of the health policies of Trump’s second term and was by the president’s side earlier this month as he signed a new executive order to pare back the list of recommended childhood vaccines and tied immunization to autism—a connection scientists say doesn’t exist.

OTHER HEADLINES

 
 

Key Upcoming Dates

 
  • 9/16: Parkinson's Disease — Evidence Report
  • 10/1: Hypertension — Evidence Report
  • 10/15: Friedrich's Ataxia — Draft Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email